The role of the central thromboxane A2 in cardiovascular effects of a phospholipase A2 activator melittin administrated intracerebroventricularly in normotensive conscious rats

Neuropeptides
Murat YalcinMelih Erturk

Abstract

The current study was designed to determine the cardiovascular effect of centrally administrated melittin, a phospholipase A2 (PLA2) activator, and the mediation of central thromboxane A2 (TXA2) and its receptors in normotensive conscious rats. Studies were performed in normotensive male Sprague Dawley rats injected intracerebroventricularly (i.c.v.) with melittin. Melittin (1.5, 3.0, 6.0 microg/5.0 microl; i.c.v.) caused dose- and time-dependent increases in mean arterial pressure (MAP) and decrease in heart rate (HR). Maximal effects were observed 5-10 min after 3.0 microg dose of melittin. In order to test the mediation of central TXA2 and its central receptors in the cardiovascular effect of melittin, the rats were pretreated with furegrelate (500.0 microg; i.c.v.), a TXA2 synthesis inhibitor, and SQ-29548 (8.0 microg; i.c.v.), a TXA2 receptor antagonist, 15 min prior to melittin (3.0 microg). Furegrelate or SQ-29548 partially inhibited the pressor effect and bradycardia elicited by melittin. In conclusion, our findings show that centrally administered melittin increases MAP and decreases HR in conscious rats. Moreover, according to our findings, central TXA2 and its receptors may in part mediate melittin-induced cardiovasc...Continue Reading

References

Oct 1, 1988·The Journal of Pharmacy and Pharmacology·G R Thomas, C R Hiley
Oct 1, 1988·Prostaglandins·G K LoveladyC W Leffler
Sep 1, 1985·Canadian Journal of Physiology and Pharmacology·A S AdeagboF Coceani
Apr 1, 1982·Prostaglandins, Leukotrienes, and Medicine·A L Sirén
Nov 1, 1982·Acta Physiologica Scandinavica·A L Sirén
Jan 14, 1999·Neuroscience Letters·G Y MolloyR J Williams
May 2, 2002·Neuroscience Letters·Hideto AriumiHiro-o Kamiya
Mar 11, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Zhi-Hua ZhangRobert B Felder
Jul 16, 2004·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Akhlaq A Farooqui, Lloyd A Horrocks
Jan 13, 2006·Clinical and Experimental Pharmacology & Physiology·Murat YalcinVahide Savci

❮ Previous
Next ❯

Citations

Jul 30, 2014·Canadian Journal of Physiology and Pharmacology·Burcin AltinbasMurat Yalcin
Jun 11, 2011·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Murat Yalcin, Cenk Aydin
Nov 17, 2009·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Murat YalcinVahide Savci
Jun 24, 2008·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Cenk Aydin, Murat Yalcin
Apr 2, 2011·Biochemical and Biophysical Research Communications·Yi-Ru DuJun Chen
Jan 1, 2015·Autonomic Neuroscience : Basic & Clinical·Kazuo AndoShoshiro Okada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.